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1. ABSTRACT  
 
Many tumor antigens have been identified that can be targeted by the immune system. Animal models that have been 
genetically modified to express human HLA molecules instead of their own MHC antigens have shown to be valuable in the 
discovery of peptides derived from tumor antigens many of which have since been used in clinical trials with varying degrees of 
success. Although these models are not perfect, they nonetheless allow transplantable tumor models to be developed to evaluate 
novel vaccination strategies that can then be applied in humans. In addition animals that have been genetically modified to 
“spontaneously” generate tumors that will grow within their correct environment are of greater value for studying angiogenesis, 
metastasis and the relationship between the immune system and tumor in a physiological setting. In this review, mice genetically 
modified to express HLA genes or to spontaneously develop tumors are discussed, highlighting their advantages and limitations 
as preclinical models for cancer immunotherapy.  
 
2. INTRODUCTION  
 
Cancer is a diverse group of diseases characterized by indefinite and uncontrolled cell proliferation. Overall one can 
say that tumor development is the result of a series of genetic alterations which have occurred in a multistep fashion within one 
cell over many years eventually leading to the emergence of a clone which no longer responds to its environment nor is 
controlled by the same signals that govern normal cell growth. As a consequence of such genetic changes, cell signaling and 
regulatory pathways in transformed cells are disturbed, giving growth advantages, modifying the micro-environment of the tumor 
cells and promoting escape mechanism from immunosurveillance. In addition, very early on in the disease progression, new 
blood vessels are created; inflammatory cells are recruited and activated in the surrounding stroma of the tumor. The interactions 
between tumor cells, immune cells, blood vessels and stroma cells are very complex and it is not possible to reproduce and study 
them in in vitro cell cultures. This is where mouse models of cancer, including genetically engineered mice (transgenic) and 
transplantable tumor models have proved indispensable tools to investigate the molecular and cellular mechanisms of tumor 
growth, as well as their applications in cancer research. Indeed, in spite of the various advances in the diagnosis and treatment of 
cancer, the conventional modalities of treatment have been unable to significantly decrease the mortality rate in patients 
diagnosed with advanced disease. There is therefore a great need for additional therapy that could specifically eliminate tumor 
cells whatever their location in the body but leave healthy tissue intact. Immunotherapy aims at manipulating/educating the 
patient’s own immune system to arm it against tumor cells so that only transformed cells are killed. Tumor cells differ from 
normal cells by the accumulation and retention of many genetic alterations such as mutation, amplification, deletion, and 
translocation, which leads to over-production of self proteins, re-expression of proteins normally only expressed by certain 
organs and/or at a certain stage of the development, or production of mutated proteins, all referred to as tumor antigens. The first 
human tumor antigen was MAGE-1 discovered by Thierry Boon’s lab (1); since then many more candidate genes have been 
added to the list.  
 
All proteins produced by the cell, whether normal or abnormal, are degraded by enzymes complexes called 
proteasomes. This proteasomal machinery generates numerous peptides, which are then associated with newly synthesized Major 
Histocompatability Complex (MHC) class-I molecules and subsequently transported to the cell surface. Most nucleated cells will 
express MHC class-I molecules and these are consistently surveyed by CD8+ T cells. Extracellular proteins are, on the other 
hand, first internalized by antigen presenting cells, by endocytosis or phagocytosis, encapsulated into endosomes and then 
degraded in the endocytic vacuoles. A phenomenon referred to as “cross-priming” can also occur where exogenous proteins are 
either processed by the proteasome thereby joining the class-I pathway or are first cleaved using the class-II pathway but then get 
transferred into the endoplasmic reticulum where they are trimmed further to fit into the groove of MHC class-I (2). The majority 
  
of peptides resulting from endocytic digestion however will bind to MHC class II molecules, which are mainly expressed by 
monocytes, macrophages, dendritic cells and B-cells and are surveyed by CD4+ T cells. 
 
One of the first steps needed to initiate the cascade of events that will eventually lead to an immune response is the 
physical interaction between the T-cell receptor (TCR) on the surface of a T lymphocyte and an antigenic peptide on the surface 
of an antigen presenting cell. TCRs interact with peptides “presented” by cell-surface MHC molecules. Foreign peptides 
presented on a cell, for example following viral infection, are recognized by T cells specific for these peptides and the cell is 
destroyed by cytolytic or apoptotic-induced mechanisms. Neo-antigens (abnormal self proteins arising during neoplastic 
transformation) may be recognized by the immune system as foreign and are potential targets for T cell mediated cellular killing. 
It is therefore of considerable importance to identify immunogenic and naturally (endogenously) processed MHC class-I and 
class-II peptides derived from tumor antigens in order to assess their potential as vaccines against cancer. It is also essential to 
learn more about the immune system / tumor relationship in a setting that resemble human tumor to understand the immune 
mechanisms of tumor rejection. 
This review describes how HLA transgenic mice and genetically engineered mice developing spontaneous cancer can 
help answer specific questions, important for the generation of future cancer vaccines. However both models have many 
advantages and disadvantages and those are briefly summarized in Table 1. 
  
3. TRANSPLANTABLE TUMOURS IN MICE TRANSGENIC FOR HUMAN MHC MOLECULES 
 
There are a number of different approaches that can be adapted for the identification of new MHC class I/II-restricted 
target antigens for immunotherapy and many of these are in fact complimentary.  
HHDII transgenic mice provide a good model for the study of HLA-A2 restricted T cells responses in vivo (3). These 
animals are “knockout” for H-2 genes, expressing instead an MHC class I molecule, consisting of the human HLA-A2.1 α1 and 
α2 domains, the murine H-2Dbα3, transmembrane and cytoplasmic class I heavy chain regions which have been covalently 
linked to human β2-microglobulin, allowing for HLA-A2 restricted antigens presentation within the context of the murine 
immune system (3). These mice have been shown to have an improved capacity to mount HLA-A2-restricted CTL responses 
compared with HLA-A2 transgenic mice (HLA-A2+/+/human beta2m+/+) that still express endogenous murine H-2b class I 
molecules (4). They represent a versatile animal model for CTL epitope mapping and preclinical characterization of HLA-A2-
restricted CTL responses. Using HHDII transgenic mice, we have screened the Prostatic Acid Phosphatase (PAP) and HAGE 
proteins for immunogenic HLA-A2-derived peptides and defined three novel epitopes (5, 6). This was confirmed and expanded 
by Machlenkin et al who were able to show that the class-I PAP-derived peptide (PAP135) pulsed onto dendritic cells could 
delay tumor growth in a preventative setting but also, and more importantly, could increase survival of mice bearing palpable 
tumor at the time of vaccination (7). Although CTL generated in HHDII mice were able to kill appropriate target cells pulsed 
with peptide, they were unable to kill human HLA-A2+ targets naturally expressing the antigen of interest. This is probably due 
to the fact that, unless CD8+ T cells generated are of very high avidity for the peptide, the recognition of the target cells by CD8+ 
T cells requires not only contact between the MHC/peptide and TCR but also between the CD8 chain and the α3 domain of the 
MHC class I molecule from the same species. This would explain why several in vitro stimulations are necessary to obtain 
murine CD8+ T cells capable of killing antigen expressing human cancer cells (8). Still using the HHDII mice as a screening 
model, it is possible to assess the immunogenicity of several peptides as well as various modified peptide and even the 
immunogenicity of different fractions of peptides eluted from tumor cells upon the generation of CTL (9, 10). CTL generated 
with peptides modified at critical anchoring position, which would increase their binding affinity to specific HLA haplotypes, 
have been shown not only to recognize and kill target cells pulsed with the modified peptide but also recognize and kill target 
cells pulsed with the wild type sequence (9). Moreover HHDII mice have proved to be a useful model to study, assess, and 
compare the efficiency of different vaccines such as naked plasmid DNA encoding either multi-epitopes for HLA class-I and 
class-II peptides, or whole protein sequence either in a single agent or in a prime-boost regimen (11, 12). We have, ourselves, 
been able to show CTL activities of splenocytes from HHDII mice immunized with gold labeled DNA encoding the entire human 
mutated (at position 273) p53 protein and stimulated once in vitro with peptide 65, 149, 264 and 217 against RMAS/A2 cells 
pulsed with the same peptides with the exception of RMAS-A2 cells pulsed with the 264 peptide which were not killed (13). 
These results are in accordance with previously published work where peptide 264 was reported not to be naturally processed 
from p53 protein mutated at position 273 (14). It is therefore possible to use HHDII mice not only to identify immunogenic 
peptides but also and more importantly, to test whether these are endogenously processed from natural or mutated cancer protein 
and although the emphasis in this review is on HLA-A2 transgenic mice, HLA-A2 being the most common class-I allele, other 
HLA transgenic mice also exist and have also been used (Table 2). Some authors have, however, reported that the peptide 
repertoire resulting from the endogenous processing of the HPV derived protein by the HHDII mice may differ to that of human 
and caution should be taken when extrapolating the data obtained using these mice to human (15). It is therefore important to 
verify data obtained in these mice using PBMCs from healthy donors and/or cancer patients.  
 
Cerundolo’s group used the inability of conventional human HLA-A2 tetramers to bind to the murine CD8 molecules 
in the HHDII mice to show that high avidity T cells which are independent of CD8 binding can be specifically identified and 
isolated from these mice (16). The group then produced HLA-A2 tetramer engineered to lack the human CD8 binding capacity in 
order to demonstrate selective binding of these tetramers to high avidity human CTL (16). The avidity of a given T cell clone is 
  
the resulting strength of the overall interactions of MHC/peptide (binding affinity) and TCR, co-stimulatory molecules and the 
extracellular microenvironment. High avidity has been linked with T cell priming and its response to a given antigen. A 
correlation between the overall avidity and the ability of a T cell clone to recognize and kill tumor cells has also been shown (17). 
This avidity is generally broadly measured by the antigen dose required to induce a T cell response, where low amounts of 
antigen (>100 nM peptide loaded on antigen presenting cells) are required for high avidity T cell generation. These results are of 
great importance since cancer can be viewed as a chronic disease and TCR affinity/avidity has been shown to be the primary 
driving force underlying repertoire of chronic antigenic stimulation (18). 
 
HLA class II transgenic mice were first designed to study auto-immune disease (19, 20, 21). Although, it is now 
accepted that CD4+ T cells play a major role in initiating and maintaining CD8+ immune responses (22) as well as helping in the 
development of memory CD8+ T cells (23). More recently, Sherman’s group were able to demonstrate yet another role to these 
cells, that of facilitating entry of CD8+ T cells into the tumor microenvironment (24).  Only a limited number of T-helper 
epitopes have been identified to date (25, 26). With this in mind, HLA class II transgenic mice expressing HLA class II 
molecules in the absence of murine class II molecules (Aβ0/0) have been generated and used for the screening of immunogenic 
HLA class II peptide epitopes of variable chain length. HLA-DR4+/+/IE0/0 and HLA-DR1/IE0/0 transgenic mice are such mice and 
can be used to study human CD4+ T cell immune response (27) as well as for the identification of MHC class II peptides. These 
mice have also recently been shown to have an enhanced efficacy over the HLA-DR1 +/+/IAbeta+/+mice (22, 23). Using these 
HLA-DR4+/+/IE0/0 and HLA-DR1+/+/IE0/0 mice we have successfully identified four novel class-II derived peptides derived from 
p53, PAP and HAGE proteins (5, 6, 30). We were, indeed able to show specific HLA-DR-restricted proliferation and cytokine 
production by splenocytes derived from p53, PAP or HAGE peptide immunized animals. Moreover mature BM-DC pre-pulsed 
with p53 overexpressing tumor lysate were recognized by CD4+ T cells generated with the same peptide. The immunogenicity of 
these HLA-DR-restricted peptides was subsequently confirmed using HLA-DR4/DR1 PBMC from healthy donors, reinforcing 
the value of utilizing HLA transgenic mice as a pre-screening method (30).  
 
Overall, we and others have found that HLA transgenic mice recognize the same antigenic determinants as those 
recognized by human T cells (31, 32) demonstrating the usefulness of such mice in finding natural tumor derived or virally 
derived epitopes that can be used in clinical trials.  
 
There has been considerable interest in the generation of mice, which are transgenic for both human class I and class II 
molecules and knockout for the murine class I and class II molecules and some have succeeded. Indeed, the HHDII/DR1 mice are 
not only double transgenic for HLA-A2 and HLA-DR1 but are also double knockout meaning that these mice survive with only 
human MHC molecules expressed on the surfaces of their cells. Using these mice, we were able to show that specific class-I and 
class-II responses can be generated simultaneously after immunization with BM-DC transiently transfected with HAGE plasmid 
(Figure 1). Indeed splenocytes derived from HHDII/DR1 transgenic mice immunized with one round of mature syngeneic Bone-
marrow derived dendritic cells (BM-DC) transfected to express the HAGE protein and stimulated once in vitro with either 
peptide HAGE126, HAGE338 or HAGE 506 were assessed for both cytotoxic responses and proliferation. Specific killing in 
those stimulated in vitro with HAGE126 could be demonstrated reaching almost 40% of total cell lysis in four out of six mice 
tested (Figure 1A). As a control experiment, HHDII/DR1 transgenic mice received one round of syngeneic BM-DC transfected 
with an empty plasmid and splenocytes were re-stimulated in vitro with peptide HAGE126. No cytotoxic response was achieved 
in both mice tested indicating that CD8+ T cell responses observed earlier were actually due to the immunization with syngeneic 
BM-DC expressing HAGE and not the in vitro re-stimulation (Data not shown). Moreover, supernatants from the in vitro re-
stimulation culture were harvested on day 3 and day 5 to measure IFNγ production by ELISA. Peptide HAGE126 allowed 
significant levels of peptide-specific IFNγ secretion on both days. These results were later confirmed when HHDII/DR1 mice 
were immunized with one round of syngeneic BM-DC pulsed with a HAGE-positive K562 cell lysate, and in vitro re-stimulation 
with HAGE126 peptide. Indeed, peptide-specific cytotoxic response of 25% was achieved in one out of two mice (Data not 
shown). Splenocytes re-stimulated in vitro with peptides HAGE338 or HAGE 506 for one week followed by CD8+ depletion and 
a week of rest with the presence of low level of murine IL-2 in the media were then co-cultured with BM-DC matured overnight 
with LPS and for 2 hours the next day with PolyIC prior to the addition of the peptide. Cultures were incubated for approximately 
60 hours at 370C, and (3H)-thymidine was added at 37kBq/well in the last 18 hours of incubation. Plates were harvested onto 96 
Uni/Filter plates (Packard), the scintillation liquid (Microscint 0, Packard) was added and the plates were counted on a Top-
Count counter (Packard). Specific proliferation was observed with both peptides HAGE 338 and HAGE 506-II (Figure 1B and 
1C). This proliferation was shown to be HLA-DR restricted since the addition of an HLA-DR antibody (L243) could inhibit the 
proliferation whereas the isotype control could not. Specific release of IFNg was also observed with both peptides mainly on day 
3 with however also a production of IL-5 by peptide HAGE338 but only on day 3 (data not shown). 
 
Some groups have also been able to generate mice transgenic for class I molecules as well as a tumor antigen (33). 
Both of these models will prove extremely useful for investigating the role of CD4+ T cells in the generation of CTL and their 
anti-tumoral effect. These mice will also allow the study of tolerance towards tumor antigens and subsequently ways of 
overcoming it; the answer of which will bring us closer to a better immunotherapeutic strategy for the treatment of human cancer.  
 
Single and now double transgenic mice expressing only human HLA molecules can therefore be used to screen 
potential immunogenic epitopes, as well as assessing many different strategies for cancer vaccinations. These can include 
  
peptides, “string” of peptides or DNA/virus based vaccines administrated in a prime boost regimen with different adjuvants. 
Indeed, DNA based therapy using 12 peptides derived from the HER2/ErbB-2 gene was shown not only to induce peptide 
specific CTL responses in both HHDII mice and HLA-A2 human in vitro stimulated PBMC but was also capable of significantly 
delaying the in vivo growth of challenged ErbB-2-expressing tumor (EL4/HHD/neu murine thymoma) (34). These mice will also 
help towards the optimization of adoptive transfer therapy and the development of sensitive tools for the immune monitoring the 
immune system for the effects of cancer immunotherapy. 
 
The antigen processing machinery, including specific proteasomal cleavage, TAP proteins, and chaperones, in human 
and mouse do however differ slightly and the overall antigen digestion and transportation may give rise to different peptide 
repertoire in transgenic mice and in humans. It is also known that the expression of several HLA haplotypes within one cell will 
induce competition between peptides thereby altering the outcome of the peptide repertoire presented by a given individual and 
thus rendering it different to the one found using HLA-single or double transgenic mice. 
 
Importantly all these studies rely on the use of transplantable tumors, which although useful to address some very 
precise questions, are limited when it comes to studying/targeting the local microenvironment including newly grown blood 
vessels feeding the tumor and the metastases. In these cases, transplantable tumors will be of no real use since most of them 
rarely metastasize and do not have the same relationship with their immediate surrounding due to their artificial implantation at a 
site which differs to the one where they originated. In an attempt to remediate to this downfall of transplantable tumors, 
Rosenblatt’s group established a very elegant model of breast cancer metastasis where both the breast cancer cells and the bone 
target are of human origin (35). In this model the engrafted human bone was shown to be functional with B cells and human IgG 
detected in the blood stream of the mice. Moreover, the injection of a human cell line derived from a metastatic nodule of a breast 
cancer patient induced metastasis to the human engrafted bone and lung of the mice. This model is thereby unique in its 
capability of reproducing the physiological events observed in breast cancer patients with bone metastasis and it will therefore 
become possible to better understand osteotropism, mechanism which commonly occurs in breast and prostate cancer but for 
which only a mice prostate cancer model was available.   
 
4. GENETICALLY ENGINEERED MICE SPONTANEOUSLY DEVELOPING TUMOURS 
 
Mouse models for cancer have existed for more than a century with the initial model being the “tumor prone inbred 
mice” where mice susceptible to developing tumors were bred over and over until the establishment of a strain of mice with high 
incidence of developing spontaneous or carcinogen-induced tumor was achieved (36). Thereafter advancement in genetic 
manipulation, has made it possible to genetically modify specific genes using gene targeting strategies in order to obtain mice, 
engineered for conditional gene expression of transforming genes, such as SV40 or polyomas, in a specific tissue (e.g the 
transgenic adenocarcinoma mouse prostate cancer model: TRAMP). Others have been genetically manipulated so that a cell or 
tissue-specific promoter will drive the expression of an oncogene known to be at the origin of tumor formation (e.g. breast cancer 
model: where HER2/neu gene is under the control of the mouse mammary tumor virus (MMTV) promoter/enhancer (37)). Both 
systems generate mice with tumors that will spontaneously develop in a particular organ and many models have been generated; 
Table 3 highlights many of them. These may not, however, match exactly the origin of the cell type found in human tumors; 
indeed, TRAMP mice, for example, develop prostate tumors of seminal origin instead of an epithelial one. However, those tumor 
models offer the advantage of spontaneously developing in the organ of interest. They also provide information that may be more 
relevant to cancer development in humans where the tumor is initiated in vivo by the clonal expansion from a single cell. 
Moreover injection of numerous tumor cells, as in the case of transplantable tumor models, may trigger inflammatory signals 
which may act in favor of the development of appropriate immune responses or may instead promote immuno-editing leaving 
behind immune-resistant subclones. By contrast, spontaneous tumors develop in a slow, progressive manner that may evoke 
reduced immune recognition and selection. Therefore immunotherapy against these tumors can be more difficult to raise, 
mimicking the challenges faced when using immunotherapy against self antigens in human tumors. It is also becoming clear that 
the tumor microenvironment greatly influences the outcome of immunotherapy and therefore requires careful evaluation. 
Recently, Wall e. al. (38) modified the MMTV/neu model to express at the end of the rat neu gene the dominant class-I and a 
class-II epitopes derived from ovalbumin. These mice were further engineered and expressed then also a dominant-negative 
mutant of p53 (DNp53, R172H) under the control of the whey acid protein (WAP) promoter in order to accelerate tumor 
formation. Using this new model, they were able to show that using the same number of adoptively transferred T cells (CD4+ and 
CD8+) both regression and non-regression responses could be obtained within the same mice, implying that these therapeutic 
responses were largely dictated by local, inherent properties of the tumor rather than systemic immunologic effects. 
 
This study highlights again how important and influential the tumor microenvironment may be on the outcome of 
immunotherapy. Most tumor associated antigens are only expressed at certain points during tumor progression or are 
constitutively expressed at low level by normal cells; therefore one other major problem is the potential to develop immune 
tolerance, which is more likely to occur in mice developing spontaneous, slow growing tumors than transplantable tumors. Using 
the TRAMP model, Matteo’s group highlighted that tumor antigen in spontaneously arising tumors are indeed seen as “self” 
antigen and vaccination strategies such as intradermal injection of peptide-pulsed DCs can have an influence on disease 
progression (39); while Gilboa’s group (40), were able to demonstrate that an mRNA vaccine encoding tumor-associated 
antigens and GM-CSF could efficiently prime CTL responses in this model. However this was unable to overcome tolerance, 
  
shown to occur at the thymic level (central tolerance) as a single adoptive transfer of naive wild type splenocytes prior to the first 
immunization led to the specific production of CTL capable of infiltrating the tumor and reducing the prostate cancer grade. It 
was therefore concluded that such vaccines although very efficient in generating high avidity CD8+ T cells are not sufficient to 
generate CTL against self antigens in animals bearing spontaneous tumors. Naive T cells are known to rapidly proliferate and 
differentiate into effector cells (TE) shortly after encountering their appropriate antigen on antigen presenting cells in vivo. As the 
antigen is cleared, these cells will die leaving only a small fraction of residual central (TCM) and effector (TEM) memory T cells.  
Memory T cells persist a lifetime and can respond very quickly upon re-exposure to the same antigen by differentiating into TE. 
Central (TCM) and effector (TEM) memory T cells which are usually discriminated by their cell surface markers, functional 
characteristics and migratory properties (40). Future therapy involving adoptive transfer needs to consider carefully which 
memory cell subtypes are more likely to survive longer in vivo and their therapeutic efficacy against established tumors. Using a 
spontaneous gp100+ murine melanoma cell line (41), Restifo’s group were able to show differences between the two CD8+ 
memory subtypes in their ability to migrate to secondary lymphoid organs and not to the tumor itself as previously thought, 
which is required for optimal tumor eradication. This suggests that TCM cells might be more suited for adoptive transfer against 
large tumors with additional tumor-antigen vaccination (42).  
 
Another advantage of using genetically engineered mice is the possibility of studying naturally occurring metastasis, 
which can be targeted after removal of the primary tumor thereby getting closer to the human development of the disease. New 
generations of transgenic mice have since been developed which have specific somatic mutations that are induced by tissue 
specific and time-controlled manner.  These are better models because the surrounding stroma cells are left “untouched”, i.e. non-
mutated by the procedure, and therefore their influence over tumor growth can then be studied with more relevance to the 
development of human tumors. Many different strategies have been employed to achieve this and for a more comprehensive 
review on this subject one can read the very good review by Jonkers and Berns (43). 
 
However, the main drawback of many of these spontaneous models is the difficulty in generating large cohort of mice 
bearing tumors at the same stage of tumor development in order to perform large experiments. Results published so far were 
obtained when tumors were still relatively small and the question remains whether these immuno-based therapies would still be 
as effective against larger tumors.  
 
5. CONCLUSION 
 
In conclusion, transgenic mice for HLA molecules are useful for the identification of naturally endogenously processed 
immunogenic peptides derived from tumor associated antigens and can be used to assess different vaccines strategies whether 
these are peptide-based vaccines with strong adjuvants, DNA/virus-based vaccines, chemotherapy alone or in combination with 
immunotherapy. However, these models do have their limitations in mimicking the human peptides repertoire and do not take 
into account the “natural” micro-environment of the origin of the tumor cells which have been transplanted, also they are not 
subject to the same mechanisms of tolerance and most of them do not spontaneously metastasize. This is why many researchers 
have turned to genetically engineered mice that “spontaneously” develop tumors within the relevant tissue, although not 
necessarily the same cell type as found in human cancers. One future possibility would be to develop a mouse model that is 
transgenic for human HLA molecules and “spontaneously” develops tumors in the appropriate tissue.  Such models have started 
to emerge with the recent generation of an HLA-A2 transgenic mice mouse model developing spontaneous melanoma by the 
group of Prevost-Blondel (44). Although this model is still not ideal because the site where the first tumor developed is different 
to that in human i.e all the mice developed ocular melanoma first, they still carry their own MHC molecules and can still help 
understand why although strong CD8-mediated immune responses are detected in mice with melanoma, the disease continues to 
progress and metastasize ultimately leading to the death of the animal. The authors have shown that MHC and antigen expression 
are both tumor and animal-specific with a strong overall down regulation of both of these in visceral lesions. However, it should 
be noted that studying the MHC expression at varying time points can alter these results. For example in this study MHC 
expression was determined after culturing the tumor cells in vitro for a few days whilst in our hands a model of transplantable 
colorectal cancer (CT26) in BALB-C mice showed that overnight culturing of tumors generated from progressing animals was 
sufficient to restore the strong down-regulation of MHC expression which was initially observed when tumor cells had been 
excised from the animal and stained immediately (45).  It would be of interest to assess CD4+ T cell involvement and more 
specifically the level of Treg present in these animals since systemic ignorance, anergy and immunoediting cannot explain the 
growth of these cutaneous tumors. 
 
At present time, no single mouse model will cover the full spectrum of the human disease and researchers whilst 
developing new models, need to bear in mind the limitations imposed by the developing tumor and its microenvironment and the 
differences existing between mouse and human, such as in the Toll-like receptor family (46). Toll-like receptors (TLRs) belong 
to a family of receptors called pattern recognition receptors (PRRs) which are used by the innate cells to recognize conserved 
pathogen-associated molecular patterns (PAMPs) expressed by microorganisms. To date 10 TLRs have been identified in human 
and 12 in mice. Their expression and stimulation have however been shown to differ between human and mice (46). Indeed TLR-
2 for example which recognizes bacterial lipopeptides is present in mouse T-cells but not in human, and TLR-3 which recognizes 
double-stranded RNA is expressed by mouse macrophages but not human macrophages (47, 48). On the other hand TLR-4, 
which recognizes glycolipid of the gram-negative bacteria, although very similar in both species, is differentially regulated by 
  
LPS. In human monocytes/macrophages incubated with LPS TLR-4 expression increases whereas it is downregulated in mouse 
macrophages (47). 
 
One should therefore be very careful in trying to translate any results obtained with either model into clinic. Some 
scientists have even started to question the entire usefulness of these models proposing to go straight to treatment.    
 
6. ACKNOWLEDGEMENTS 
 
This work was supported by European Commission, Contracts LSHC-CT-2004-503306 (ENACT) and ESTDAB 
(QLRI-CT-2000-01325), the John and Lucille van Geest Foundation. We are also grateful to Stephen Reeder for excellent 
technical support and Morgan Mathieu for providing the HAGE data. The author wishes to thank Prof. R. C. Rees for his help in 
editing this manuscript. 
 
7. REFENCES 
 
1. van der Bruggen V, C. Traversari, P. Chomez,  P. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, T. Boon. A gene 
encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma: Science 254, 1643-7 (1991) 
 
2. Palmowski M.J, U. Gileadi, M. Salio, A. Gallimore, M. Millrain, E. James, C. Addey, D. Scott, J. Dyson, E. Simpson, V. 
Cerundolo. Role of immunoproteasomes in cross-presentation: J Immunol 177, 983-90 (2006) 
 
3. Pascolo S, N. Bervas, J.M. Ure, A.G. Smith, F.A. Lemonnier, B. Perarnau. HLA-A2.1-restricted education and cytolytic 
activity of CD8 (+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double 
knockout mice: J Exp Med 185 (12), 2043-51 (1997) 
 
4. Ramage J.M, R. Metheringham, R. Moss, I. Spendlove, R. Rees, L.D. Durrant. Comparison of the immune response to a self 
antigen after DNA immunisation of HLA*A201/H-2Kb and HHD transgenic mice: Vaccine 22, 1728-31 (2004)  
5. Miles A, A. Roger, R. Parkinson, R. Rees, S.E.B. McArdle: Overview of prostate biomarkers as potential targets for 
immunotherapy. Current Cancer Therapy Reviews. In press. 
 
6. Mathieu M.G, A.J Knights, G. Pawelec, C.L. Riley, D. Wernet, F.A. Lemonnier, P.T Straten, L. Mueller, R.C Rees, S.E. 
McArdle. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II 
HAGE-derived immunogenic peptides: Cancer Immunol Immunother 56, 1885-95 (2007)  
 
7. Machlenkin A, R. Azriel-Rosenfeld, I. Volovitz, E. Vadai, A. Lev, A. Paz, O. Goldberger, Y. Reiter, E. Tzehoval, I. Benhar, L. 
Eisenbach. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma 
development in HLA transgenic mice: Cancer Immunol Immunother  56, 217-26 (2007)  
 
8. Pascolo S, M. Schirle, B. Guckel, T. Dumrese, S. Stumm, S. Kayser, A. Moris, D. Wallwiener, H.G. Rammensee, S. 
Stevanovic: A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 61, 4072-7 (2001) 
 
9. Corbet S, H.V. Nielsen, L.Vinner, S. Lauemoller, D. Therrien, S. Tang, G. Kronborg, L. Mathiesen, P. Chaplin, S. Brunak, S. 
Buus, A. Fomsgaard: Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency 
virus type 1-specific CTL epitopes. J Gen Virol 84, 2409-21 (2003)  
 
10. Gritzapis A.D, N.N. Sotiriadou, M. Papamichail, C.N. Baxevanis. Generation of human tumor-specific CTLs in HLA-A2.1-
transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors: Cancer Immunol 
Immunother 53, 1027-40 (2004) 
 
11. Shi T.D, Y.Z. Wu, Z.C Jia, W. Zhou, L.Y. Zou. Therapeutic polypeptides based on HBcAg (18-27) CTL epitope can induce 
antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice: World J Gastroenterol 10, 1222-6 (2004)  
 
12. Himoudi N, J.D. Abraham, A. Fournillier, Y.C. Lone, A. Joubert, A. Op De Beeck, D. Freida, F. Lemonnier, M.P. Kieny, 
G.J. Inchauspe. J Virol. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes 
presented in hepatitis C virus natural infection: J Virol 76, 12735-46 (2002) 
 
13. Muller L, S. McArdle, E. Derhovanessian, T. Flad, A. Knights, R. Rees, G. Pawelec. Current Strategies for the Identification 
of Immunogenic Epitopes of Tumor Antigens. Immunotherapy of Cancer. Publisher Humana, Press (2007) 
 
14. Theobald M, T. Ruppert, U. Kuckelkorn, Hernandez J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C, 
Koszinowski UH, Kloetzel PM, Sherman LA: The sequence alteration associated with a mutational hotspot in p53 protects cells 
from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med. 188, 1017-28 (1998) 
  
15. Street M.D, T. Doan, K.A. Herd, R.W. Tindle: Limitations of HLA-transgenic mice in presentation of HLA-restricted 
cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunol. 106, 526–536 (2002) 
  
16. Choi E.M, J.L. Chen, L. Wooldridge, M. Salio, A. Lissina, N. Lissin, I.F. Hermans, J.D. Silk, F. Mirza, M.J. Palmowski, P.R. 
Dunbar, B.K. Jakobsen, A.K. Sewell, V. Cerundolo: High avidity antigen-specific CTL identified by CD8-independent tetramer 
staining. J Immunol 171, 5116-23 (2003) 
 
17. Johnson L.A, B. Heemskerk, D.J. Powell Jr, C.J. Cohen, R.A. Morgan, M.E. Dudley, P.F. Robbins, S.A. Rosenberg: Gene 
transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to non reactive peripheral blood mononuclear cells 
and tumor-infiltrating lymphocytes. J Immunol 177, 6548-59 (2006)  
 
18. Trautmann L, M. Rimbert, K. Echasserieau, X. Saulquin, B. Neveu, J. Dechanet, V. Cerundolo, M. Bonneville: Selection of T 
cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses. J Immunol 175, 
6123-32 (2005)  
 
19. Altmann D.M, D.C. Douek, A.J. Frater, C.M. Hetherington, H. Inoko, J.I. Elliott: The T cell response of HLA-DR transgenic 
mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J. Exp. Med. 181, 867 (1995) 
20. Woods A, H.Y. Chen, M.E. Trumbauer, A. Sirotina, R. Cummings, D.M. Zaller: Human major histocompatibility complex 
class II-restricted T cell responses in transgenic mice. J. Exp. Med 180, 173 (1994) 
 
21. Kong Y.M, C.S. David, L.C. Lomo, B.E. Fuller, R.W. Motte, A.A. Giraldo: Role of mouse and human class II transgenes in 
susceptibility to and protection against mouse autoimmune thyroiditis. Immunogenetics 46, 312 (1997) 
 
22. Assudani D.P, R.B. Horton, M.G. Mathieu, S.E. McArdle, R.C. Rees: The role of CD4+ T cell help in cancer immunity and 
the formulation of novel cancer vaccines. Cancer Immunol Immunother 56, 70-80 (2007) 
 
23. Janssen E.M, N.M. Droin, E.E. Lemmens, M.J. Pinkoski, S.J. Bensinger, B.D. Ehst, T.S. Griffith, D.R. Green, S.P. 
Schoenberger: CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434, 
88-93 (2005) 
 
24. Wong S.B, R. Bos, L.A. Sherman: Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration 
by Low-Avidity CD8+ T Cells. J Immunol 180, 3122-31 (2008) 
 
25. Wilson C.C, B. Palmer, S. Southwood, J. Sidney, Y. Higashimoto, E. Appella, R. Chesnut, A. Sette, B.D. Livingston: 
Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-
lymphocyte epitopes. J Virol 75, 4195-207 (2001)  
 
26. Boritz E, B.E. Palmer, B. Livingston, A. Sette, C.C. Wilson: Diverse repertoire of HIV-1 p24-specific, IFN-gamma-
producing CD4+ T cell clones following immune reconstitution on highly active antiretroviral therapy. J. Immunol 170, 1106 
(2003) 
 
27. Sonderstrup G, A.P. Cope, S. Patel, M. Congia, N. Hain, F.C. Hall, S.L. Parry, L.H. Fugger, S. Michie, H.O. McDevitt: HLA 
class II transgenic mice: models of the human CD4+ T-cell immune response. Immunol Rev 172, 335-43 (1999) 
 
28. Pajot A, V. Pancre, N. Fazilleau, M.L. Michel, G. Angyalosi, D.M. Ojcius, C. Auriault, F.A. Lemonnier, Y.C. Lone: 
Comparison of HLA-DR1-restricted T cell response induced in HLA-DR1 transgenic mice deficient for murine MHC class II and 
HLA-DR1 transgenic mice expressing endogenous murine MHC class II molecules. Int Immunol 16, 1275-82 (2004)  
 
29. Firat H, M. Cochet, P.S. Rohrlich, F. Garcia-Pons, S. Darche, O. Danos, F.A. Lemonnier, P. Langlade-Demoyen: 
Comparative analysis of the CD8 (+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 
transgenic mice. Int Immunol 14, 925-34 (2002) 
 
30. Rojas J.M, S.E. McArdle, R.B. Horton, M. Bell, S. Mian, G. Li, S.A. Ali, R.C. Rees: Peptide immunisation of HLA-DR-
transgenic mice permits the identification of a novel HLA-DRbeta1*0101- and HLA-DRbeta1*0401-restricted epitope from p53. 
Cancer Immunol Immunother 54, 243-53 (2005) 
 
31. Ressing M.E, A. Sette, R.M. Brandt, J. Ruppert, P.A. Wentworth, M. Hartman, C.  Oseroff, H.M. Grey, C.J. Melief, W.M. 
Kast: Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro 
immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 154, 5934-43 (1995) 
 
  
32. Chandwani R, K.A Jordan, B.L. Shacklett, E. Papasavvas, L.J. Montaner, M.G. Rosenberg, D.F. Nixon, J. K. Sandberg: 
Limited magnitude and breadth in the HLA-A2-restricted CD8 T-Cell response to Nef in children with vertically acquired HIV-1 
infection. Scand J Immunol 59, 109-14 (2003) 
 
33. Zhou H, Y. Luo, M. Mizutani, N. Mizutani, J.C. Becker, F.J. Primus, R. Xiang, R.A. Reisfeld. A novel transgenic mouse 
model for immunological evaluation of carcinoembryonic antigen-based DNA minigene vaccines. J Clin Invest 113, 1792-8 
(2004) 
 
34. Scardino A, M. Alimandi, P. Correale, S.G. Smith, R. Bei, H. Firat, M.G. Cusi, O. Faure, S. Graf-Dubois, G. Cencioni, J. 
Marrocco, S. Chouaib, F.A. Lemonnier, A.M. Jackson, K. Kosmatopoulos: A polyepitope DNA vaccine targeted to Her-2/ErbB-
2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res 67, 7028-36 (2007) 
 
35. Kuperwasser C, S. Dessain, B.E. Bierbaum, D. Garnet, K. Sperandio, G.P. Gauvin, S..P Naber, R.A. Weinberg, M. 
Rosenblatt: A mouse model of human breast cancer metastasis to human bone. Cancer Res 65, 6130-8 (2005)  
 
36. Morse H.C. Origins of Inbred Mice. Academic Press (1978) 
 
37. Guy C.T, R.D. Cardiff, W.J. Muller: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a 
transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-61 (1992) 
 
38. Wall E.M, K. Milne, M.L. Martin, P.H. Watson, P. Theiss, B.H. Nelson: Spontaneous mammary tumors differ widely in their 
inherent sensitivity to adoptively transferred T cells. Cancer Res 67, 6442-50 (2007) 
 
39. Degl'Innocenti E, M. Grioni, A. Boni, A. Camporeale, M.T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N.M. 
Greenberg, M. Bellone: Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be 
rescued by dendritic cell immunization. Eur J Immunol 35, 66-75 (2005) 
 
40. Hess P.R, D. Boczkowski, S.K. Nair, D. Snyder, E. Gilboa: Vaccination with mRNAs encoding tumor-associated antigens 
and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome 
tolerance to a model tumor/self antigen. Cancer Immunol Immunother 55, 672-83 (2006) 
 
41. Geginat J, F. Sallusto, A. Lanzavecchia: Cytokine-driven proliferation and differentiation of human naïve, central memory 
and effector memory CD4+ T cells. Pathol Biol 51, 64-6 (2003)  
 
42. Overwijk W.W, M.R. Theoret, S.E. Finkelstein, D.R. Surman, L.A. de Jong, F.A. Vyth-Dreese, T.A. Dellemijn, P.A. Antony, 
P.J. Spiess, D.C. Palmer, D.M. Heimann, C.A. Klebanoff, Z. Yu, L.N. Hwang, L. Feigenbaum, A.M. Kruisbeek, S.A. Rosenberg, 
N.P. Restifo: Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J 
Exp Med 198, 569-80 (2003) 
 
43. Klebanoff C.A, L. Gattinoni, P. Torabi-Parizi, K. Kerstann, A.R. Cardones, S.E. Finkelstein, D.C. Palmer, P.A. Antony, S.T. 
Hwang, S.A. Rosenberg, T.A. Waldmann, N.P. Restifo: Central memory self/tumor-reactive CD8+ T cells confer superior 
antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 102, 9571-6 (2005) 
 
44. Jonkers J, A. Berns:  Conditional mouse models of sporadic cancer. Nat Rev Cancer 2, 251-65 (2002) 
 
45. Lengagne R, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.G. Guillet, V.H. Engelhard, M.F. Avril, J.P. Abastado, A. 
Prevost-Blondel: Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases. J Immunol 180, 130-7 (2008)  
 
46. Ahmad M, R.C. Rees, S.E. McArdle, G. Li, S: Mian, C. Entwisle, P. Loudon, S.A. Ali: Regulation of CTL responses to 
MHC-restricted class I peptide of the gp70 tumour antigen by splenic parenchymal CD4+ T cells in mice failing immunotherapy 
with DISC-mGM-CSF. Int J Cancer 115, 951-9 (2005) 
 
47. Rehli M. Of mice and men: species variations of Toll-like receptor expression. Trends Immunol 23, 375-8 (2002)  
 
48. Muzio M, D. Bosisio, N. Polentarutti, G. D'amico, A. Stoppacciaro, R. Mancinelli, C. van't Veer, G. Penton-Rol, L.P. Ruco, 
P. Allavena, A. Mantovani: Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective 
expression of TLR3 in dendritic cells. J Immunol 164, 5998-6004 (2000) 
 
49. Matsuguchi T, T. Musikacharoen, T. Ogawa, Y. Yoshikai: Gene expressions of Toll-like receptor 2, but not Toll-like receptor 
4, is induced by LPS and inflammatory cytokines in mouse macrophages. J Immunol 165, 5767-72 (2000) 
  
50. Pajot A, M.L. Michel, N. Fazilleau, V. Pancre, C. Auriault, D.M. Ojcius, F.A. Lemonnier, Y.C. Lone: A mouse model of 
human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur J Immunol 34, 
3060-9 (2004)  
 
51. Altmann D.M, D.C. Douek, A.J. Frater, C.M. Hetherington, H. Inoko, J.I. Elliott: The T cell response of HLA-DR transgenic 
mice to human myelin basic protein and other antigens in the presence and absence of human CD4. J Exp Med 181, 867-875 
(1995) 
 
52. Ito K, H.J. Bian, M. Molina, J. Han, J. Magram, E. Saar, C. Belunis, D.R. Bolin, R. Arceo, R. Campbell, F. Falcioni, D. 
Vidovic, J. Hammer, Z.A. Nagy: HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to 
experimental allergic encephalomyelitis. J Exp Med 183, 2635-44 (1996) 
 
53. Alexander J, C. Oseroff, J. Sidney, P. Wentworth, E. Keogh, G. Hermanson, F.V. Chisari, R.T. Kubo, H.M. Grey, A. Sette: 
Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes. J 
Immunol 159, 4753-61 (1997) 
 
54. Barra C, B. Perarnau, P. Gerlinger, M. Lemeur, A. Gillet, P. Gibier, F.A Lemonnier : Analysis of the HLA-Cw3-specific 
cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice. J Immunol 143, 3117-24 (1989) 
 
55. Kalinke U, B. Arnold, G.J. Hämmerling: Strong xenogeneic HLA response in transgenic mice after introducing an alpha 3 
domain into HLA B27. Nature 348, 642-4 (1990) 
 
56. Gotoh M, H.Takasu, K. Harada, T. Yamaoka: Development of HLA-A2402/K (b) transgenic mice. Int J Cancer 100, 565-70 
(2002) 
 
57. Yamamoto K, Y. Fukui, Y. Esaki, T. Inamitsu, T. Sudo, K. Yamane, N. Kamikawaji, A. Kimura, T. Sasazuki: Functional 
interaction between human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecule in antigen recognition 
by T cells in HLA-DR and DQ transgenic mice. J Exp Med 180, 165-71 (1994) 
 
58. Schonbach C, K. Nokihara, C.R. Bangham, A. Kariyone, S. Karaki, H. Shida, K. Takatsu, K. Egawa, K.H. Wiesmüller, M. 
Takiguchi: Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 
transgenic mice. Virology 226, 102-12 (1996) 
 
59. Guy C.T, R.D. Cardiff, W.J. Muller: Induction of mammary tumors by expression of polyomavirus middle T oncogene: a 
transgenic mouse model for metastatic disease. Mol Cell Biol 12, 954-61 (1992) 
 
60. Rowse G.J, R.M. Tempero, M.L. VanLith, M.A. Hollingsworth, S.J. Gendler: Tolerance and immunity to MUC1 in a human 
MUC1 transgenic murine model. Cancer Res 58, 315-21 (1998) 
 
61. Mukherjee P, C.S. Madsen, A.R. Ginardi, T.L. Tinder, F. Jacobs, J. Parker, B. Agrawal, B.M. Longenecker, S.J. Gendler: 
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 26, 47-62 (2003) 
 
62. Greenberg N.M, F. DeMayo, M.J. Finegold, D. Medina, W.D. Tilley, J.O. Aspinall, G.R. Cunha, A.A. Donjacour, R.J. 
Matusik, J.M. Rosen: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 92, 3439-43 (1995) 
 
62. Abate-Shen C, M.M. Shen: Mouse models of prostate carcinogenesis. Trends Genet 18, S1-5 (2002) 
 
63. Garbe A.I, B. Vermeer, J. Gamrekelashvili, R. von Wasielewski, F.R. Greten, A.M. Westendorf, J. Buer, R.M. Schmid, M.P. 
Manns, F. Korangy, T.F. Greten: Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous 
tumor-specific immune responses. Cancer Res 66, 508-16 (2006) 
 
64. Tuveson D.A, A.T. Shaw, N.A. Willis, D.P. Silver, E.L. Jackson, S. Chang, K.L. Mercer, R. Grochow, H. Hock, D. Crowley, 
S.R. Hingorani, T. Zaks, C. King, M.A. Jacobetz, L. Wang, R.T. Bronson, S.H. Orkin, R.A. DePinho, T. Jacks: Endogenous 
oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375-87 
(2004) 
 
65. Flesken-Nikitin A, K.C. Choi, J.P. Eng, E.N. Shmidt, A.Y. Nikitin: Induction of carcinogenesis by concurrent inactivation of 
p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63, 3459-63 (2003)  
 
66.  Hinoi T, A. Akyol, B.K. Theisen, D.O. Ferguson, J.K. Greenson, B.O. Williams, K.R. Cho, E.R. Fearon: Mouse model of 
colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Res 67, 9721-30 (2007) 
 
  
67.  Meuwissen R, A. Berns: Mouse models for human lung cancer. Genes Dev 19, 643-64 (2005) 
 
68. Meuwissen R, S.C. Linn, R.I. Linnoila, J. Zevenhoven, W.J. Mooi, A. Berns: Induction of small cell lung cancer by somatic 
inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4, 181-9 (2003) 
 
 
 
 
Key Words: Transgenic mice, genetically modified mice, immunotherapy, cancer. 
 
Send correspondence to: Stephanie McArdle, The John van Geest Cancer Research Centre,  School of Science and Technology, 
Nottingham Trent University, Clifton Lane, Nottingham, NG11 8NS, UK, Tel: +44 (0) 115 848 6684, Fax: +44 (0) 115 848 
3384,  E-mail: stephanie.mcardle@ntu.ac.uk. 
 
Running title: MHC transgenic mice compared to genetically modified mice 
 
 
  
 
Table 1. Comparative relevance of both models 
Model using mice transgenic  for HLA molecules 
 
Genetically engineered mice developing spontaneous tumors 
Metastasize only in the lung when injected intravenously and 
rarely at other sites 
Frequent metastasis with a distribution which often reflect 
those in human  
Wrong microenvironment Appropriate microenvironment 
Relatively inexpensive labor  Labor intensive 
Allow the identification of clinically relevant peptides Peptides are specific for mice of the same strain 
Allow the assessment of different vaccines strategies but 
response may differ depending on the tumor implantation. 
Allow the assessment of different vaccine strategies with 
responses more relevant due to their correct localization. 
 
 
Table 2. List of HLA-transgenic mice (non exhaustive) 
 
Table 3. Examples of existing spontaneous tumor models in mice 
Cancer model Genetic modifications References 
Breast Cancer Mice expressing the polyomavirus middle-T oncogene driven by the 
mouse mammary tumor virus (MMTV) long-terminal repeat (LTR) these 
develop spontaneous mammary carcinomas.MUC1 transgenic mice 
(MUC1.Tg) expressing the human MUC1 antigen in a tissue-specific 
fashion similar to that in humans.MMT mice expressing the PyMT and 
the MUC1 antigen and develop spontaneous mammary carcinomas. 
 (58) (59) (60) 
Prostate Cancer C57BL/6 inbred TRAMP mice were generated by microinjection of a 
construct harboring a minimal rat probasin (PB) -426/+28 regulatory 
element to direct expression of the SV40 early genes (T and t antigens; 
Tag) to prostatic epithelium in a developmentally and hormonally 
regulated fashion. 
 (61)For a more comprehensive 
review on spontaneous prostate 
cancer refer to Abate-Shen C 
and Shen MM (62) 
Pancreatic 
Adenocarcinoma 
P53-deficient mice and TGF-α human growth hormone (hGH) fusion 
gene under the control of the Elastase (El) promoter (EL-TGF-a-hGH 
transgenic mice backcrossed on CD57BL/6. Develop rapidly growing 
tumors in the pancreas within 120 days after birth. 
 (63) (64) 
Ovary Cancer Cre-adenovirus/ p53+RB1 floxed recipients where more than 90% of the 
mice develop progressive and metastatic ovarian tumors 
 (65) 
Colon 
adenocarcinoma 
C57BL6/J mice carrying the ApcMin mutation were intercrossed with 
mice carrying the CDX2P 9.5-NLS Cre allele. These developed mainly 
colorectal tumors, with carcinomas seen in 6 of 36 (17%) of mice 
followed for 300 days. 
 (66) 
Lung Cancers Various models  (67) and (68) 
Melanoma MT-ret mice were crossed with AAD mice expressing a chimeric MHC 
class I composed of the α1 and α2 domains of HLA-A*0201 and the 3 
domain of H2-Dd (31) to produce MT-ret+/–/AAD+/– (MT-ret/AAD) 
mice. More than 85% of the MT-ret/AAD mice (n = 101) displayed 
tumors within 4 mo after birth, and 50% of them had several evident 
cutaneous nodules at day 64. 
 (44) 
 
 
HLA-type Mice background References 
HLA-A2 H-2 class-I KO   C57BL/6  (3) 
HLA-A2 and HLA-DR1 H-2 class-I/class-II KO C57BL/6  (49) 
HLA-A3 H-2 KO C57BL/6  (3) 
HLA-DR1 FVB/N  (50) 
HLA-DR4/IE C57BL/6  (51) 
HLA-A11/ Kb C57BL/6  (52) 
HLA-B7/Kb and class-I KO C57BL/6  (53) 
HLA-A27/Kb C57BL/6  (54) 
HLA-A24 H-2 class-I KO C57BL/6  (55) 
HLA-DQ6 and HLA-DR51 C57BL/6  (56) 
HLA-B35 C57BL/6  (57) 
  12 
Figure 1. Cytotoxicity and proliferation assays were performed using splenocytes cells generated from HHDII/HLA-DR1 
transgenic mice immunized with DC transiently transfected with pSHAME2a/HAGE and re-stimulated with either HAGE-
derived class I peptide (126) (A), or HAGE-derived class II peptide 338 (B) or peptide 506 (C). Standard 4hrs chromium release 
assay was carried out after in vitro re-stimulation of immunized cells with immunogenic HAGE-derived class I peptides. 
Cytokine analysis was carried out on supernatants harvested on day 3 and 5 of the in vitro re-stimulation with HAGE peptide 
(data not shown). Specific killing can be seen against target cells pulsed with HAGE126 compared to those pulsed with an 
irrelevant one. Specific release of IFNg was also observed with all tested peptides mainly on day 3 with however also a 
production of IL-5 by peptide HAGE338 but only on day 3 (data not shown). Proliferation assays were carried out after in vitro 
re-stimulation of immunized cells with HAGE 338 (A) and HAGE 506 (B) followed by a resting period of one week with low 
level of murine IL-2.  For the proliferation mature BM-DC pulsed with either the relevant or irrelevant peptide were co-cultured 
with the CD8- rested splenocytes for 60 hours with the addition of radio-active thymidine (3H) during the last 18 hours. Results 
are expressed in counts per minute (cpm) and as means of the quadruplicate wells. Specific proliferation could be detected when 
the cells from immunized animals were co-cultured with DC-pulsed with the specific HAGE-derived peptides whether it be 
HAGE338 or HAGE506. The addition of an HLA-DR antibody in the culture was able to specifically inhibit this proliferation for 
both peptides whereas isotype control was not.  *p<0.05, **p<0.01, ***p<0.001 are the statistical differences between HAGE-
derived peptides and Irrelevant determined by unpaired Student T test.   
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